Second-generation antipsychotics for major depressive disorder and dysthymia
- PMID:21154393
- DOI: 10.1002/14651858.CD008121.pub2
Second-generation antipsychotics for major depressive disorder and dysthymia
Abstract
Background: Major depressive disorder (MDD) is a common condition with a lifetime prevalence of 15% to 18%, which leads to considerable suffering and disability. Some antipsychotics have been reported to induce remission in major depression, when added to an antidepressant.
Objectives: To evaluate the effects of second-generation antipsychotic (SGA) drugs (alone or augmentation) compared with placebo or antidepressants for people with MDD or dysthymia.
Search strategy: The Cochrane Depression, Anxiety and Neurosis Group's controlled trial registers (CCDANCTR-Studies and CCDANCTR-References) were searched up to 21 July 2010. The author team ran complementary searches on clinicaltrials.gov and contacted key authors and drug companies.
Selection criteria: We included all randomised, double-blind trials comparing oral SGA treatment (alone or augmentation) with other forms of pharmaceutical treatment or placebo in people with MDD or dysthymia.
Data collection and analysis: We extracted data independently. For dichotomous data we calculated the odds ratio (OR) and 95% confidence interval (CI) on an intention-to-treat basis, and for continuous data the mean difference (MD), based on a random-effects model. We presented each comparison separately; we did not perform a pooled data analysis.
Main results: We included 28 trials with 8487 participants on five SGAs: amisulpride, aripiprazole, olanzapine, quetiapine and risperidone.Three studies (1092 participants) provided data on aripiprazole augmentation in MDD. All efficacy data (response n = 1092, three RCTs, OR 0.48; 95% CI 0.37 to 0.63), (MADRS n = 1077, three RCTs, MD -3.04; 95% CI -4.09 to -2) indicated a benefit for aripiprazole but more side effects (weight gain, EPS) .Seven trials (1754 participants) reported data on olanzapine. Compared to placebo fewer people discontinued treatment due to inefficacy; compared to antidepressants there were no efficacy differences, olanzapine augmentation showed symptom reduction (MADRS n = 808, five RCTs, MD -2.84; 95% CI -5.48 to -0.20), but also more weight or prolactin increase.Quetiapine data are based on seven trials (3414 participants). Compared to placebo, quetiapine monotherapy (response n = 1342, three RCTs, OR 0.52; 95% CI 0.41 to 0.66) and quetiapine augmentation (response n = 937, two RCTs, OR 0.68; 95% CI 0.52 to 0.90) showed symptom reduction, but quetiapine induced more sedation.Four trials (637 participants) presented data on risperidone augmentation, response data were better for risperidone (n = 371, two RCTs, OR 0.57; 95% CI 0.36 to 0.89) but augmentation showed more prolactin increase and weight gain.Five studies (1313 participants) presented data on amisulpride treatment for dysthymia. There were some beneficial effects compared to placebo or antidepressants but tolerability was worse.
Authors' conclusions: Quetiapine was more effective than placebo treatment. Aripiprazole and quetiapine and partly also olanzapine and risperidone augmentation showed beneficial effects compared to placebo. Some evidence indicated beneficial effects of low-dose amisulpride for dysthymic people. Most SGAs showed worse tolerability.
Similar articles
- Risperidone versus other atypical antipsychotics for schizophrenia.Komossa K, Rummel-Kluge C, Schwarz S, Schmid F, Hunger H, Kissling W, Leucht S.Komossa K, et al.Cochrane Database Syst Rev. 2011 Jan 19;(1):CD006626. doi: 10.1002/14651858.CD006626.pub2.Cochrane Database Syst Rev. 2011.PMID:21249678Free PMC article.Review.
- Second-generation antipsychotics for obsessive compulsive disorder.Komossa K, Depping AM, Meyer M, Kissling W, Leucht S.Komossa K, et al.Cochrane Database Syst Rev. 2010 Dec 8;(12):CD008141. doi: 10.1002/14651858.CD008141.pub2.Cochrane Database Syst Rev. 2010.PMID:21154394Review.
- Ziprasidone versus other atypical antipsychotics for schizophrenia.Komossa K, Rummel-Kluge C, Hunger H, Schwarz S, Bhoopathi PS, Kissling W, Leucht S.Komossa K, et al.Cochrane Database Syst Rev. 2009 Oct 7;(4):CD006627. doi: 10.1002/14651858.CD006627.pub2.Cochrane Database Syst Rev. 2009.PMID:19821380Free PMC article.Review.
- Second-generation antipsychotics for anxiety disorders.Depping AM, Komossa K, Kissling W, Leucht S.Depping AM, et al.Cochrane Database Syst Rev. 2010 Dec 8;(12):CD008120. doi: 10.1002/14651858.CD008120.pub2.Cochrane Database Syst Rev. 2010.PMID:21154392Review.
- An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.Krzystanek M, Krupka-Matuszczyk I.Krzystanek M, et al.Hum Psychopharmacol. 2011 Jan;26(1):81-5. doi: 10.1002/hup.1173. Epub 2011 Feb 9.Hum Psychopharmacol. 2011.PMID:23055416Review.
Cited by
- Thoughtful prescribing for patients with difficult-to-treat depression.Soubolsky A, Visentin J, Crawley A.Soubolsky A, et al.Can Fam Physician. 2023 Nov;69(11):777-783. doi: 10.46747/cfp.6911777.Can Fam Physician. 2023.PMID:37963783Free PMC article.No abstract available.
- Antipsychotic, antidepressant, and cognitive-impairment properties of antipsychotics: rat profile and implications for behavioral and psychological symptoms of dementia.Kołaczkowski M, Mierzejewski P, Bienkowski P, Wesołowska A, Newman-Tancredi A.Kołaczkowski M, et al.Naunyn Schmiedebergs Arch Pharmacol. 2014 Jun;387(6):545-57. doi: 10.1007/s00210-014-0966-4. Epub 2014 Mar 6.Naunyn Schmiedebergs Arch Pharmacol. 2014.PMID:24599316Free PMC article.
- Predictors of time to relapse/recurrence after electroconvulsive therapy in patients with major depressive disorder: a population-based cohort study.Nordenskjöld A, von Knorring L, Engström I.Nordenskjöld A, et al.Depress Res Treat. 2011;2011:470985. doi: 10.1155/2011/470985. Epub 2011 Nov 3.Depress Res Treat. 2011.PMID:22110913Free PMC article.
- Real-World Economic Outcomes of Brexpiprazole and Extended-Release Quetiapine Adjunctive Use in Major Depressive Disorder.Seetasith A, Greene M, Hartry A, Burudpakdee C.Seetasith A, et al.Clinicoecon Outcomes Res. 2019 Dec 4;11:741-755. doi: 10.2147/CEOR.S220007. eCollection 2019.Clinicoecon Outcomes Res. 2019.PMID:31824181Free PMC article.
- A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder.Hobart M, Zhang P, Skuban A, Brewer C, Hefting N, Sanchez R, McQuade RD.Hobart M, et al.J Clin Psychopharmacol. 2019 May/Jun;39(3):203-209. doi: 10.1097/JCP.0000000000001034.J Clin Psychopharmacol. 2019.PMID:30946704Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous